Skip to main content
. 2020 Jun 6;85:106683. doi: 10.1016/j.intimp.2020.106683

Table 1.

Characteristics of neutrophil to CD4+ lymphocyte ratio in patients with COVID-19 pneumonia.

Variable (unit, normal range) Total (n = 95) ≤ 0.012533 (n = 48) > 0.012533 (n = 47) P value
Female, No. (%) 51 (53.6) 34 (70.8) 17 (36.2) 0.001
Age, mean ± SD 55 ± 16 50 ± 15 60 ± 16 0.006
Comorbidities, No. (%)
Cardiovascular/cerebrovascular 28 (29.4) 11 (22.9) 17 (36.2) 0.157
Respiratory 6 (6.3) 1 (2.1) 5 (10.6) 0.111
Endocrine 23 (24.2) 10 (20.8) 13 (27.6) 0.437
Nervous 3 (3.1) 1 (2.1) 2 (4.2) 0.617
Urinary 1 (1.1) 0 (0) 1 (2.1) 0.495
Hepatic 8 (8.4) 4 (8.3) 4 (8.5) 1.000
Symptoms and signs, No. (%)
Fever 64 (67.3) 27 (56.2) 37 (78.7) 0.020
Fatigue 32 (33.6) 8 (16.7) 24 (51.1) P < 0.001
Headache 2 (2.1) 2 (4.2) 0 (0) 0.495
Cough 36 (37.8) 14 (29.2) 22 (46.8) 0.076
Chest distress/breath shortness 36 (37.8) 8 (16.7) 28 (59.6) P < 0.001
Anorexia 2 (2.1) 0 (0) 2 (4.2) 0.242
Diarrhea 1 (1.1) 1 (2.1) 0 (0) 1.000
Severity assessment on admission, No. (%)
General 56 (58.9) 40 (83.3) 16 (34.0) P < 0.001
Serious 15 (15.8) 6 (12.5) 9 (19.1)
Critical 24 (25.2) 2 (4.2) 22 (46.8)
Hospitalized treatment, No. (%)
Corticosteroid 58 (61.1) 19 (39.6) 39 (82.9) P < 0.001
Mechanical ventilation 23 (24.2) 2 (4.2) 21 (44.7) P < 0.001
Virus negative conversion time, median (IQR) 19 (11–27) 13 (9–21) 24 (18–33) P < 0.001

Abbreviation: COVID-19, coronavirus disease 2019; No., number; SD, standard deviation; IQR, interquartile range.